Nautilus Biotechnology Partners with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation for Parkinson's Disease Research

Wednesday, Jan 28, 2026 2:32 pm ET1min read
NAUT--

Nautilus Biotechnology (NAUT) has partnered with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation to study the alpha-synuclein protein's role in Parkinson's disease. The project is backed by a $1.6 million grant and utilizes Nautilus's advanced single-molecule proteomics platform. Despite being in the development stage, Nautilus has strong financial health with a current ratio of 14.95 and a debt-to-equity ratio of 0.16. However, investors should be aware of the company's developmental stage and inherent sector risks.

Nautilus Biotechnology Partners with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation for Parkinson's Disease Research

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet